Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
TRV GP II, LLC (CIK 1614073) reported $1.3M across 1 reported positions in its SEC 13F filing for 2022-09-30. Largest positions: JNCE ($1.3M, 100.00%), ALNAQ ($0, 0.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | JNCE | JOUNCE THERAPEUTICS, INC. | $1.3M | 100.00% | 572,829 | Trimmed |
| 2 | ALNAQ | ALLENA PHARMACEUTICALS, INC. | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2022-09-30